263 related articles for article (PubMed ID: 34940556)
1. Iron, Heme Synthesis and Erythropoietic Porphyrias: A Complex Interplay.
Poli A; Schmitt C; Moulouel B; Mirmiran A; Puy H; Lefèbvre T; Gouya L
Metabolites; 2021 Nov; 11(12):. PubMed ID: 34940556
[TBL] [Abstract][Full Text] [Related]
2. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability.
Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X
Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834
[TBL] [Abstract][Full Text] [Related]
3. The role of ClpX in erythropoietic protoporphyria.
Whitman JC; Paw BH; Chung J
Hematol Transfus Cell Ther; 2018; 40(2):182-188. PubMed ID: 30057992
[TBL] [Abstract][Full Text] [Related]
4. Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations.
Weiss Y; Balwani M; Chen B; Yasuda M; Nazarenko I; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):358-362. PubMed ID: 30454868
[TBL] [Abstract][Full Text] [Related]
5. Delta-aminolevulinic acid synthase 2 expression in combination with iron as modifiers of disease severity in erythropoietic protoporphyria.
Barman-Aksözen J; Halloy F; Iyer PS; Schümperli D; Minder AE; Hall J; Minder EI; Schneider-Yin X
Mol Genet Metab; 2019 Nov; 128(3):304-308. PubMed ID: 31076252
[TBL] [Abstract][Full Text] [Related]
6. Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria.
Di Pierro E; Granata F; De Canio M; Rossi M; Ricci A; Marcacci M; De Luca G; Sarno L; Barbieri L; Ventura P; Graziadei G
Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054318
[TBL] [Abstract][Full Text] [Related]
7. Porphyrias and photosensitivity: pathophysiology for the clinician.
Kakoullis L; Louppides S; Papachristodoulou E; Panos G
Postgrad Med; 2018 Nov; 130(8):673-686. PubMed ID: 30296862
[TBL] [Abstract][Full Text] [Related]
8. Heme Biosynthetic Gene Expression Analysis With dPCR in Erythropoietic Protoporphyria Patients.
Granata F; Brancaleoni V; Barman-Aksözen J; Scopetti M; De Luca G; Fustinoni S; Motta I; Di Pierro E; Graziadei G
Front Physiol; 2022; 13():886194. PubMed ID: 35923227
[No Abstract] [Full Text] [Related]
9. Hematologic aspects of the porphyrias.
Sassa S
Int J Hematol; 2000 Jan; 71(1):1-17. PubMed ID: 10729988
[TBL] [Abstract][Full Text] [Related]
10. Clinical Guide and Update on Porphyrias.
Stölzel U; Doss MO; Schuppan D
Gastroenterology; 2019 Aug; 157(2):365-381.e4. PubMed ID: 31085196
[TBL] [Abstract][Full Text] [Related]
11. Clinically important features of porphyrin and heme metabolism and the porphyrias.
Besur S; Hou W; Schmeltzer P; Bonkovsky HL
Metabolites; 2014 Nov; 4(4):977-1006. PubMed ID: 25372274
[TBL] [Abstract][Full Text] [Related]
12. Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model.
Abitbol M; Puy H; Sabaté JM; Guénet JL; Deybach JC; Montagutelli X
Physiol Res; 2006; 55 Suppl 2():S93-101. PubMed ID: 17298226
[TBL] [Abstract][Full Text] [Related]
13. Iron Metabolism in the Disorders of Heme Biosynthesis.
Ricci A; Di Betto G; Bergamini E; Buzzetti E; Corradini E; Ventura P
Metabolites; 2022 Aug; 12(9):. PubMed ID: 36144223
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the iron-sulfur cluster ligands of the human ferrochelatase lead to erythropoietic protoporphyria.
Schneider-Yin X; Gouya L; Dorsey M; Rüfenacht U; Deybach JC; Ferreira GC
Blood; 2000 Aug; 96(4):1545-9. PubMed ID: 10942404
[TBL] [Abstract][Full Text] [Related]
15. Heme biosynthesis and the porphyrias.
Phillips JD
Mol Genet Metab; 2019 Nov; 128(3):164-177. PubMed ID: 31326287
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.
Balwani M
Mol Genet Metab; 2019 Nov; 128(3):298-303. PubMed ID: 30704898
[TBL] [Abstract][Full Text] [Related]
17. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria.
Delaby C; Lyoumi S; Ducamp S; Martin-Schmitt C; Gouya L; Deybach JC; Beaumont C; Puy H
Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):45-52. PubMed ID: 19268001
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of protoporphyrin IX from delta-aminolevulinic acid in bovine skin fibroblasts with hereditary erythropoietic protoporphyria. A gene-dosage effect.
Sassa S; Schwartz S; Ruth G
J Exp Med; 1981 May; 153(5):1094-101. PubMed ID: 6788885
[TBL] [Abstract][Full Text] [Related]
19. Protoporphyrin accumulation by mitogen stimulated lymphocytes and protoporphyrinogen oxidase activity in patients with porphyria variegata and erythropoietic protoporphyria: evidence for deficiency of protoporphyrinogen oxidase and ferrochelatase in both diseases.
Siepker LJ; Kramer S
Br J Haematol; 1985 May; 60(1):65-74. PubMed ID: 3924091
[TBL] [Abstract][Full Text] [Related]
20. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.
Yasuda M; Chen B; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):320-331. PubMed ID: 30594473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
